Can GLP-1 Receptor Agonists and SGLT2 Inhibitors Treat Diabetic Neuropathy?
Diabetic nerve damage affects roughly one in three people with diabetes, and a review asks whether the world’s most talked-about diabetes drugs can treat it.
- Diabetic sensorimotor polyneuropathy (DSPN) affects about one third of people with diabetes and remains underdiagnosed and undertreated, according to the review.
- Current pain drugs relieve symptoms only; combination analgesic therapy helps at most 54% of patients, the authors report.
- Laboratory and small clinical studies suggest GLP-1 receptor agonists may support nerve fibre regrowth, but large placebo-controlled trials have not yet confirmed disease modification.
A common complication with no disease-modifying drug
The review, titled “Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal,” examines whether two widely prescribed drug classes can do what current treatment cannot: slow the underlying nerve damage of diabetic sensorimotor polyneuropathy rather than only mute its pain.
DSPN is the most frequent form of diabetic neuropathy and contributes to increased mortality and considerable morbidity, the authors write. It damages protective sensation, drives foot ulcers and produces neuropathic pain that sharply reduces quality of life. Recent evidence also links neuropathy to prediabetes, obesity and metabolic syndrome, not only established diabetes.
Management today rests on three cornerstones: lifestyle change with optimized glucose and cardiovascular risk control, pathogenetic pharmacotherapy, and symptomatic treatment of neuropathic pain. For symptomatic relief, analgesic drugs do not target the neuropathy itself, and their efficacy is limited — combination therapy achieves a 54% response rate at best, the review states. Dose-limiting adverse events often restrict the analgesics that do work.
Intensive glucose lowering partly prevents or slows DSPN in type 1 diabetes, but the authors note there is no consistent evidence for the same effect in type 2 diabetes. Alpha-lipoic acid has strong evidence in DSPN, yet the reviewers conclude that therapies built on the disease's pathogenesis are still needed.
Why GLP-1 receptor agonists are candidates
Glucagon-like peptide-1 receptor agonists such as semaglutide — and the dual agonist tirzepatide, which also targets the glucose-dependent insulinotropic polypeptide receptor — are established treatments for type 2 diabetes and obesity. Their proven benefits extend beyond glucose control to cardiovascular and renal outcomes. The question the authors pose is whether those same metabolic effects reach the peripheral nerves.
A companion review summarizes the preclinical case. Immunohistochemical studies indicate that both GLP-1 receptor agonists and dipeptidyl peptidase 4 inhibitors promote neurite outgrowth, neuronal survival, ion conduction and Schwann cell function in experimental models. Intra-epidermal nerve fibre density — a direct measure of the small nerve fibres in skin — has been reported to increase with treatment in both drug classes.
Electrophysiological work points mostly to beneficial effects on motor and sensory nerve conduction velocity, and behavioural tests in animal models resembling neuropathic symptoms supported those findings. Limited clinical data have shown improved somatosensory-evoked potentials, better vibration perception thresholds, and restored nerve excitability and size parameters. Both reviews converge on the same caution: clinical evidence is promising but thin.
What the trials have tested so far
The critical appraisal weighs efficacy and safety data from randomized controlled trials of both GLP-1 receptor agonists and SGLT2 inhibitors — the sister class that blocks glucose reabsorption in the kidney, driving urinary glucose excretion of 40 to 80 grams per day and lowering HbA1c by roughly 0.5 to 0.7% in type 2 diabetes. That same glucosuric mechanism raises the class’s primary side effect, genitourinary infections.
What the reviews do not establish is clinical practice. Neither class has demonstrated disease modification in DSPN in large, double-blind placebo-controlled trials, and the authors frame their conclusion as a case for further study rather than a treatment recommendation. Patients should not expect a change to standard of care on this evidence alone; guidelines continue to centre on glucose control and pain relief.
Industry ties the authors disclose
The review carries extensive competing-interest disclosures. G.S. reports speaker fees from Procter and Gamble (P&G) Health, Viatris and Eli Lilly. D.S. reports speaker fees from Wörwag Pharma and Grünenthal, institutional research support from Withings, Abbott Laboratories, Tandem Diabetes and P&G Health, and is an executive committee member of the Novo Nordisk UK Research Foundation.
D.Z. reports consultant fees from AstraZeneca, Bayer, Clexio, Grünenthal, GSK, Novaremed, Nevro, Novo Nordisk, P&G, Syqe, TrigoCare, Viatris and Wörwag Pharma, speaker fees from AstraZeneca, Daiichi Sankyo, Eva, Grünenthal, Nevro, Sanofi, Viatris and Wörwag Pharma, and institutional research support from Wörwag Pharma.
S.T. reports consultant fees from Wörwag Pharma, Grünenthal, Nevro, Viatris, Merz and P&G Health, speaker fees from Viatris, Wörwag Pharma, Nevro, P&G Health, Grünenthal and Medtronics, and institutional research support from Withings, Viatris and P&G Health.
Who should watch this evidence
People with diabetes who have numbness, burning pain or loss of protective sensation in their feet currently rely on symptomatic therapy, and the reviews make clear that relief is incomplete. Patients whose neuropathic pain persists despite first-line treatment have reason to discuss whether a GLP-1 receptor agonist or SGLT2 inhibitor already suits their diabetes profile, since both classes carry proven cardiovascular and renal benefits independent of any nerve effect.
Neuropathy assessment tools such as monofilament and vibration testing fall to primary care clinicians and diabetologists; anyone with suspected DSPN should seek evaluation from a physician experienced in diabetic complications rather than initiate any new drug class for neuropathy on the strength of preclinical data.
The reviewers' own framing ends the argument for now: of the existing analgesic options, they write that only α-lipoic acid carries strong evidence in DSPN, and future randomized trials must show whether incretin-based therapy can move from symptom relief to nerve repair.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.